Follicular Lymphoma Grade 3B

14 clinical trials · Condition

Record	Firm	Date
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (NCT05326243)	Pell Bio-Med Technology Co., Ltd.	2022-05-31
R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden (NCT05040555)	oubai, MD/PhD	2021-08-30
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (NCT04088890)	Matthew Frank	2019-09-12
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma (NCT02855359)	Seagen Inc.	2016-08-01
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma (NCT02592876)	Seagen Inc.	2015-10-01
R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B (NCT01852435)	Ruijin Hospital	2013-05-01

Every clearance here is in the API, with alerts when new ones post.